 Stacie Daugherty
Concepts (245)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hypertension | 11 | 2022 | 1056 | 2.730 |
Why?
| | Healthcare Disparities | 11 | 2021 | 479 | 2.280 |
Why?
| | Out-of-Hospital Cardiac Arrest | 5 | 2021 | 78 | 2.150 |
Why?
| | Antihypertensive Agents | 8 | 2021 | 429 | 2.090 |
Why?
| | Sex Factors | 22 | 2022 | 1715 | 2.030 |
Why?
| | Cardiopulmonary Resuscitation | 5 | 2021 | 222 | 1.770 |
Why?
| | Medication Adherence | 5 | 2022 | 536 | 1.490 |
Why?
| | Exercise Test | 5 | 2017 | 544 | 1.410 |
Why?
| | Myocardial Infarction | 11 | 2017 | 927 | 1.280 |
Why?
| | Cardiology | 6 | 2020 | 259 | 1.160 |
Why?
| | Racism | 4 | 2021 | 102 | 1.030 |
Why?
| | Registries | 20 | 2022 | 1767 | 1.000 |
Why?
| | Cardiovascular Diseases | 6 | 2022 | 1727 | 0.940 |
Why?
| | Heart Failure | 8 | 2022 | 1945 | 0.930 |
Why?
| | Practice Guidelines as Topic | 4 | 2019 | 1394 | 0.910 |
Why?
| | Coronary Disease | 3 | 2011 | 348 | 0.880 |
Why?
| | Blood Pressure | 5 | 2019 | 1538 | 0.880 |
Why?
| | Risk Assessment | 7 | 2022 | 2967 | 0.810 |
Why?
| | Social Values | 2 | 2021 | 36 | 0.800 |
Why?
| | Angiotensin-Converting Enzyme Inhibitors | 5 | 2018 | 179 | 0.740 |
Why?
| | Defibrillators, Implantable | 6 | 2019 | 286 | 0.740 |
Why?
| | Cardiologists | 2 | 2018 | 40 | 0.730 |
Why?
| | Myocardial Ischemia | 3 | 2022 | 235 | 0.670 |
Why?
| | Pregnancy Complications, Cardiovascular | 1 | 2020 | 64 | 0.670 |
Why?
| | Death, Sudden, Cardiac | 4 | 2015 | 160 | 0.630 |
Why?
| | Public Opinion | 1 | 2019 | 59 | 0.620 |
Why?
| | Clinical Decision-Making | 2 | 2018 | 268 | 0.620 |
Why?
| | Primary Prevention | 4 | 2015 | 172 | 0.620 |
Why?
| | Attitude to Health | 1 | 2021 | 405 | 0.610 |
Why?
| | Middle Aged | 32 | 2022 | 26719 | 0.600 |
Why?
| | Radiography, Thoracic | 1 | 2019 | 150 | 0.600 |
Why?
| | Adrenergic beta-Antagonists | 5 | 2018 | 287 | 0.600 |
Why?
| | Female | 50 | 2022 | 59466 | 0.590 |
Why?
| | United States | 30 | 2022 | 12176 | 0.580 |
Why?
| | Male | 44 | 2022 | 55554 | 0.560 |
Why?
| | Atrial Fibrillation | 2 | 2018 | 322 | 0.550 |
Why?
| | Sleep Wake Disorders | 1 | 2020 | 233 | 0.550 |
Why?
| | Humans | 65 | 2022 | 114623 | 0.540 |
Why?
| | Thromboembolism | 1 | 2017 | 92 | 0.540 |
Why?
| | Warfarin | 1 | 2017 | 135 | 0.540 |
Why?
| | Follow-Up Studies | 13 | 2022 | 4411 | 0.540 |
Why?
| | Anticoagulants | 2 | 2018 | 550 | 0.540 |
Why?
| | Anemia | 1 | 2017 | 143 | 0.540 |
Why?
| | Disease Management | 2 | 2019 | 560 | 0.540 |
Why?
| | Patient Discharge | 5 | 2022 | 771 | 0.530 |
Why?
| | Sleep | 2 | 2022 | 631 | 0.510 |
Why?
| | Coronary Artery Disease | 5 | 2022 | 607 | 0.510 |
Why?
| | Hemoglobins | 1 | 2017 | 315 | 0.510 |
Why?
| | Ultrasonography | 1 | 2019 | 633 | 0.510 |
Why?
| | Aged | 25 | 2022 | 19061 | 0.500 |
Why?
| | Multimodal Imaging | 4 | 2020 | 88 | 0.490 |
Why?
| | Risk Factors | 15 | 2022 | 8628 | 0.490 |
Why?
| | Percutaneous Coronary Intervention | 3 | 2017 | 444 | 0.470 |
Why?
| | Quality of Health Care | 2 | 2020 | 573 | 0.470 |
Why?
| | Ambulatory Care | 1 | 2018 | 478 | 0.470 |
Why?
| | Practice Patterns, Physicians' | 3 | 2018 | 1177 | 0.470 |
Why?
| | American Heart Association | 5 | 2020 | 264 | 0.460 |
Why?
| | Guideline Adherence | 1 | 2018 | 490 | 0.450 |
Why?
| | Sex Distribution | 5 | 2020 | 337 | 0.430 |
Why?
| | Aged, 80 and over | 10 | 2021 | 6344 | 0.430 |
Why?
| | Hemostasis, Surgical | 1 | 2013 | 19 | 0.430 |
Why?
| | Health Status Disparities | 3 | 2021 | 200 | 0.420 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 3 | 2017 | 373 | 0.420 |
Why?
| | Blood Loss, Surgical | 1 | 2013 | 84 | 0.410 |
Why?
| | Postoperative Hemorrhage | 1 | 2013 | 74 | 0.410 |
Why?
| | Drug Resistance | 1 | 2012 | 158 | 0.390 |
Why?
| | Stroke | 3 | 2020 | 1021 | 0.360 |
Why?
| | Alaska Natives | 2 | 2022 | 117 | 0.340 |
Why?
| | Patient Selection | 2 | 2013 | 641 | 0.340 |
Why?
| | Resuscitation Orders | 2 | 2020 | 45 | 0.320 |
Why?
| | Patient Preference | 1 | 2011 | 167 | 0.320 |
Why?
| | Incidence | 7 | 2022 | 2311 | 0.310 |
Why?
| | Multivariate Analysis | 4 | 2017 | 1430 | 0.300 |
Why?
| | Electrocardiography | 1 | 2011 | 560 | 0.300 |
Why?
| | Cardiac Catheterization | 1 | 2011 | 534 | 0.280 |
Why?
| | Aspirin | 2 | 2017 | 324 | 0.280 |
Why?
| | Lung | 1 | 2019 | 3558 | 0.270 |
Why?
| | Indians, North American | 2 | 2022 | 570 | 0.270 |
Why?
| | Adult | 16 | 2022 | 30528 | 0.270 |
Why?
| | Thoracic Surgery | 2 | 2017 | 106 | 0.270 |
Why?
| | Retrospective Studies | 13 | 2020 | 12542 | 0.260 |
Why?
| | Coronary Angiography | 1 | 2008 | 304 | 0.260 |
Why?
| | Societies, Medical | 3 | 2019 | 663 | 0.260 |
Why?
| | Continuity of Patient Care | 1 | 2008 | 253 | 0.250 |
Why?
| | Heart Diseases | 2 | 2019 | 331 | 0.250 |
Why?
| | Heart Arrest | 2 | 2020 | 292 | 0.250 |
Why?
| | Heart-Assist Devices | 2 | 2022 | 485 | 0.240 |
Why?
| | Prospective Studies | 7 | 2019 | 6217 | 0.230 |
Why?
| | Young Adult | 9 | 2022 | 10455 | 0.230 |
Why?
| | Secondary Prevention | 2 | 2017 | 222 | 0.230 |
Why?
| | Prognosis | 6 | 2019 | 3328 | 0.210 |
Why?
| | Odds Ratio | 5 | 2017 | 953 | 0.210 |
Why?
| | Health Knowledge, Attitudes, Practice | 2 | 2021 | 1183 | 0.200 |
Why?
| | Intention to Treat Analysis | 1 | 2021 | 68 | 0.190 |
Why?
| | Self Report | 2 | 2022 | 696 | 0.190 |
Why?
| | Women's Health | 2 | 2016 | 271 | 0.190 |
Why?
| | Treatment Outcome | 10 | 2017 | 9084 | 0.190 |
Why?
| | Peptide Fragments | 2 | 2017 | 665 | 0.190 |
Why?
| | Hospital Mortality | 4 | 2018 | 776 | 0.190 |
Why?
| | Single-Blind Method | 1 | 2021 | 258 | 0.180 |
Why?
| | Writing | 1 | 2021 | 82 | 0.180 |
Why?
| | Professional-Patient Relations | 1 | 2021 | 141 | 0.180 |
Why?
| | Sex Characteristics | 5 | 2022 | 640 | 0.180 |
Why?
| | Telephone | 1 | 2021 | 152 | 0.170 |
Why?
| | Survival Rate | 5 | 2020 | 1644 | 0.170 |
Why?
| | Drug Therapy, Combination | 2 | 2019 | 951 | 0.170 |
Why?
| | Cohort Studies | 6 | 2020 | 4894 | 0.160 |
Why?
| | Sexuality | 1 | 2019 | 19 | 0.160 |
Why?
| | Colorado | 3 | 2021 | 4099 | 0.160 |
Why?
| | Cardiac Resynchronization Therapy Devices | 1 | 2019 | 10 | 0.160 |
Why?
| | Oropharyngeal Neoplasms | 1 | 2019 | 38 | 0.160 |
Why?
| | Electric Countershock | 1 | 2019 | 104 | 0.160 |
Why?
| | Time Factors | 6 | 2018 | 6112 | 0.160 |
Why?
| | Predictive Value of Tests | 3 | 2019 | 1796 | 0.160 |
Why?
| | Residence Characteristics | 1 | 2020 | 275 | 0.150 |
Why?
| | Congresses as Topic | 1 | 2020 | 195 | 0.150 |
Why?
| | Clinical Audit | 1 | 2018 | 11 | 0.150 |
Why?
| | Logistic Models | 4 | 2012 | 1840 | 0.150 |
Why?
| | Atherosclerosis | 1 | 2022 | 341 | 0.150 |
Why?
| | Ventricular Function | 1 | 2018 | 57 | 0.150 |
Why?
| | Heart Failure, Systolic | 1 | 2018 | 20 | 0.150 |
Why?
| | Heart Failure, Diastolic | 1 | 2018 | 20 | 0.150 |
Why?
| | Transgender Persons | 1 | 2020 | 134 | 0.150 |
Why?
| | Postmenopause | 1 | 2020 | 303 | 0.150 |
Why?
| | Patient Readmission | 2 | 2020 | 609 | 0.150 |
Why?
| | Positron-Emission Tomography | 1 | 2019 | 259 | 0.150 |
Why?
| | F Factor | 1 | 2017 | 3 | 0.150 |
Why?
| | Anesthesiology | 1 | 2017 | 35 | 0.150 |
Why?
| | Point-of-Care Systems | 1 | 2019 | 136 | 0.140 |
Why?
| | Angiotensin II Type 1 Receptor Blockers | 2 | 2017 | 29 | 0.140 |
Why?
| | Ezetimibe | 1 | 2017 | 24 | 0.140 |
Why?
| | Poverty | 1 | 2020 | 442 | 0.140 |
Why?
| | Simvastatin | 1 | 2017 | 59 | 0.140 |
Why?
| | Health Care Surveys | 1 | 2019 | 539 | 0.140 |
Why?
| | Natriuretic Peptide, Brain | 1 | 2017 | 94 | 0.140 |
Why?
| | Mortality | 2 | 2008 | 287 | 0.130 |
Why?
| | Sex Offenses | 1 | 2019 | 148 | 0.130 |
Why?
| | Chi-Square Distribution | 1 | 2017 | 493 | 0.130 |
Why?
| | Patient Protection and Affordable Care Act | 1 | 2017 | 99 | 0.130 |
Why?
| | Blood Pressure Determination | 2 | 2014 | 122 | 0.130 |
Why?
| | Heart Valve Diseases | 1 | 2017 | 161 | 0.130 |
Why?
| | Prevalence | 2 | 2019 | 2249 | 0.130 |
Why?
| | Anticholesteremic Agents | 1 | 2017 | 128 | 0.130 |
Why?
| | Diagnostic Imaging | 1 | 2017 | 275 | 0.120 |
Why?
| | Communication | 2 | 2018 | 744 | 0.120 |
Why?
| | Waiting Lists | 1 | 2017 | 211 | 0.120 |
Why?
| | Administration, Oral | 1 | 2017 | 728 | 0.120 |
Why?
| | Ambulatory Care Facilities | 2 | 2020 | 213 | 0.120 |
Why?
| | Referral and Consultation | 1 | 2019 | 632 | 0.110 |
Why?
| | Critical Care | 1 | 2018 | 476 | 0.110 |
Why?
| | Aortic Valve Stenosis | 1 | 2017 | 272 | 0.110 |
Why?
| | Heart Defects, Congenital | 1 | 2020 | 671 | 0.110 |
Why?
| | Angiography | 3 | 2020 | 174 | 0.110 |
Why?
| | Acute Coronary Syndrome | 1 | 2017 | 253 | 0.110 |
Why?
| | Decision Support Techniques | 1 | 2017 | 355 | 0.110 |
Why?
| | Depression | 1 | 2021 | 1133 | 0.110 |
Why?
| | Hemorrhage | 1 | 2017 | 620 | 0.110 |
Why?
| | Hirudins | 1 | 2013 | 46 | 0.110 |
Why?
| | Antithrombins | 1 | 2013 | 49 | 0.100 |
Why?
| | Medicaid | 1 | 2017 | 406 | 0.100 |
Why?
| | Health Personnel | 1 | 2018 | 574 | 0.100 |
Why?
| | Diuretics | 1 | 2012 | 66 | 0.100 |
Why?
| | Echocardiography | 3 | 2020 | 553 | 0.100 |
Why?
| | Dose-Response Relationship, Drug | 2 | 2013 | 1842 | 0.100 |
Why?
| | Heart Transplantation | 1 | 2017 | 665 | 0.090 |
Why?
| | Stroke Volume | 1 | 2013 | 504 | 0.090 |
Why?
| | Biomarkers | 2 | 2017 | 3408 | 0.090 |
Why?
| | Age Factors | 4 | 2022 | 2894 | 0.090 |
Why?
| | Recombinant Proteins | 1 | 2013 | 1230 | 0.080 |
Why?
| | Aftercare | 2 | 2022 | 186 | 0.080 |
Why?
| | Hospitals | 1 | 2014 | 581 | 0.080 |
Why?
| | Tomography, X-Ray Computed | 4 | 2020 | 2279 | 0.080 |
Why?
| | Medicare | 3 | 2022 | 665 | 0.080 |
Why?
| | Eligibility Determination | 1 | 2009 | 60 | 0.080 |
Why?
| | Proportional Hazards Models | 2 | 2008 | 1075 | 0.080 |
Why?
| | Pregnancy | 1 | 2020 | 5517 | 0.080 |
Why?
| | Poisson Distribution | 1 | 2008 | 71 | 0.070 |
Why?
| | Magnetic Resonance Imaging, Cine | 2 | 2017 | 172 | 0.070 |
Why?
| | Veterans | 1 | 2017 | 1248 | 0.070 |
Why?
| | Longitudinal Studies | 1 | 2012 | 2387 | 0.060 |
Why?
| | Adolescent | 6 | 2022 | 17831 | 0.060 |
Why?
| | Regression Analysis | 1 | 2008 | 944 | 0.060 |
Why?
| | Heart Rate | 1 | 2008 | 709 | 0.060 |
Why?
| | Recovery of Function | 1 | 2008 | 574 | 0.060 |
Why?
| | Primary Health Care | 1 | 2014 | 1512 | 0.060 |
Why?
| | Evidence-Based Medicine | 1 | 2008 | 668 | 0.060 |
Why?
| | Pilot Projects | 2 | 2020 | 1372 | 0.050 |
Why?
| | Cross-Sectional Studies | 2 | 2022 | 4405 | 0.050 |
Why?
| | Alaska | 1 | 2021 | 78 | 0.050 |
Why?
| | Diabetes Mellitus, Type 2 | 1 | 2014 | 2094 | 0.040 |
Why?
| | Hospitalization | 2 | 2020 | 1749 | 0.040 |
Why?
| | Risk Reduction Behavior | 1 | 2022 | 201 | 0.040 |
Why?
| | Cholesterol | 1 | 2022 | 367 | 0.040 |
Why?
| | Gender Identity | 1 | 2020 | 102 | 0.040 |
Why?
| | Age Distribution | 1 | 2020 | 342 | 0.040 |
Why?
| | Perception | 1 | 2021 | 311 | 0.040 |
Why?
| | Magnetic Resonance Spectroscopy | 1 | 2020 | 473 | 0.040 |
Why?
| | Postoperative Complications | 1 | 2009 | 2128 | 0.040 |
Why?
| | SEER Program | 1 | 2019 | 196 | 0.040 |
Why?
| | Exercise | 1 | 2008 | 1644 | 0.040 |
Why?
| | Hospitals, Rural | 1 | 2018 | 31 | 0.040 |
Why?
| | Minority Health | 1 | 2018 | 19 | 0.040 |
Why?
| | California | 1 | 2019 | 353 | 0.040 |
Why?
| | Hospitals, Urban | 1 | 2018 | 127 | 0.040 |
Why?
| | Advisory Committees | 1 | 2019 | 208 | 0.040 |
Why?
| | Risk Adjustment | 1 | 2017 | 76 | 0.040 |
Why?
| | Europe | 1 | 2017 | 334 | 0.030 |
Why?
| | Needs Assessment | 1 | 2019 | 314 | 0.030 |
Why?
| | Prosthesis Design | 1 | 2018 | 285 | 0.030 |
Why?
| | Consensus | 1 | 2019 | 537 | 0.030 |
Why?
| | Medically Uninsured | 1 | 2017 | 121 | 0.030 |
Why?
| | Caregivers | 1 | 2022 | 717 | 0.030 |
Why?
| | Veterans Health | 1 | 2017 | 165 | 0.030 |
Why?
| | Insurance Coverage | 1 | 2017 | 200 | 0.030 |
Why?
| | Frail Elderly | 1 | 2015 | 106 | 0.030 |
Why?
| | Insurance, Health | 1 | 2017 | 244 | 0.030 |
Why?
| | Linear Models | 1 | 2017 | 768 | 0.030 |
Why?
| | Survival Analysis | 1 | 2017 | 1211 | 0.030 |
Why?
| | Liver Cirrhosis | 1 | 2015 | 227 | 0.030 |
Why?
| | Intensive Care Units | 1 | 2018 | 617 | 0.030 |
Why?
| | Radial Artery | 1 | 2014 | 66 | 0.030 |
Why?
| | Physician-Patient Relations | 1 | 2018 | 462 | 0.030 |
Why?
| | United States Department of Veterans Affairs | 1 | 2017 | 560 | 0.030 |
Why?
| | Platelet Aggregation Inhibitors | 1 | 2017 | 401 | 0.030 |
Why?
| | Qualitative Research | 1 | 2018 | 934 | 0.030 |
Why?
| | Dementia | 1 | 2015 | 187 | 0.030 |
Why?
| | Clinical Trials as Topic | 1 | 2017 | 931 | 0.030 |
Why?
| | Comorbidity | 1 | 2017 | 1448 | 0.030 |
Why?
| | Cholesterol, LDL | 1 | 2014 | 307 | 0.020 |
Why?
| | Reproducibility of Results | 1 | 2019 | 2762 | 0.020 |
Why?
| | Delivery of Health Care, Integrated | 1 | 2014 | 228 | 0.020 |
Why?
| | Attitude of Health Personnel | 1 | 2018 | 975 | 0.020 |
Why?
| | Renal Insufficiency, Chronic | 1 | 2015 | 486 | 0.020 |
Why?
| | Socioeconomic Factors | 1 | 2014 | 1077 | 0.020 |
Why?
| | Obstetrics | 1 | 2011 | 146 | 0.020 |
Why?
| | Surveys and Questionnaires | 1 | 2020 | 4620 | 0.020 |
Why?
| | Gynecology | 1 | 2011 | 163 | 0.020 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 1 | 2015 | 913 | 0.020 |
Why?
| | Magnetic Resonance Imaging | 1 | 2019 | 3039 | 0.020 |
Why?
| | Diabetes Mellitus | 1 | 2015 | 900 | 0.020 |
Why?
| | Cause of Death | 1 | 2008 | 361 | 0.020 |
Why?
| | Obesity | 1 | 2017 | 2507 | 0.020 |
Why?
| | Insulin | 1 | 2014 | 2076 | 0.010 |
Why?
| | Neoplasms | 1 | 2015 | 2097 | 0.010 |
Why?
| | Child | 1 | 2020 | 18404 | 0.010 |
Why?
|
|
Daugherty's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|